Communiqués Rocket Pharmaceuticals, Inc.

Actions

RCKT

US77313F1066

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
2,560 ^USD	-2,66%		0,00%	-27,07%

08/10	Les actions de Rocket Pharmaceuticals progressent après le relèvement de recommandation de Goldman Sachs	MT
08/10	Rocket Pharmaceuticals, Inc. : Goldman Sachs neutre sur le dossier	ZM

Communiqués

07/10	Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar	BU
06/10	Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital	BU
15/09	Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease	BU
03/09	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
11/08	Rocket Pharmaceuticals: Q2 Earnings Snapshot	AQ
10/08	Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress	BU
03/08	Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease	BU
12/06	Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million	BU
28/05	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
08/05	Rocket Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Rocket Pharmaceuticals: Q1 Earnings Snapshot	AQ
07/05	Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress	BU
28/04	Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher	BU
30/03	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I	AQ
27/03	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)	BU
26/02	Rocket Pharmaceuticals: Q4 Earnings Snapshot	AQ
26/02	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress	BU
23/02	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences	BU
05/01	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
25/11	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference	BU
06/11	Rocket Pharmaceuticals: Q3 Earnings Snapshot	AQ
06/11	Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress	BU
14/10/25	Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)	BU
13/10/25	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4	AQ
13/10/25	Rocket Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ